In other cancers, the use of monoclonal antibodies that block immune checkpoints such as programmed death 1 (PD-1; PDCD1) are effective alternative therapies to mobilize the immune system6, but in sarcoma their activity has been modest7–10. The gene discussed is PDCD1; the disease is sarcoma.